Literature DB >> 12141316

Recessive inheritance and variable penetrance of slow-channel congenital myasthenic syndromes.

R Croxen1, C Hatton, C Shelley, M Brydson, G Chauplannaz, H Oosterhuis, A Vincent, J Newsom-Davis, D Colquhoun, D Beeson.   

Abstract

BACKGROUND: Slow-channel congenital myasthenic syndromes (SCCMS) typically show dominant inheritance. They are caused by missense mutations within the subunits of muscle nicotinic acetylcholine receptors (AChR) that result in prolonged ion channel activations. SCCMS mutations within the AChR subunit are located in various functional domains, whereas fully described mutations in AChR non- subunits have, thus far, been located only in the M2 channel-lining domain. The authors identified and characterized two -subunit mutations, located outside M2, that underlie SCCMS in three kinships. In two of the three kinships, the syndrome showed an atypical inheritance pattern.
METHODS: These methods included clinical diagnosis, mutation detection, haplotype analysis, and functional expression studies using single-channel recordings of mutant AChR transiently transfected into HEK293 cells.
RESULTS: The authors identified two SCCMS mutations in the AChR subunit, L78P and L221F. Both mutations prolonged ACh-induced ion channel activations. L78P is present in a consanguineous family and appears to be pathogenic only when present on both alleles, and L221F shows variable penetrance in one of the two families that were identified harboring this mutation.
CONCLUSION: SCCMS mutations may show a recessive inheritance pattern and variable penetrance. A diagnosis of SCCMS should not be ruled out in cases of CMS with an apparent recessive inheritance pattern.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12141316     DOI: 10.1212/wnl.59.2.162

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  15 in total

1.  Structure of the first transmembrane domain of the neuronal acetylcholine receptor beta2 subunit.

Authors:  Vasyl Bondarenko; Yan Xu; Pei Tang
Journal:  Biophys J       Date:  2006-12-01       Impact factor: 4.033

2.  A human congenital myasthenia-causing mutation (epsilon L78P) of the muscle nicotinic acetylcholine receptor with unusual single channel properties.

Authors:  Christopher Shelley; David Colquhoun
Journal:  J Physiol       Date:  2005-02-24       Impact factor: 5.182

3.  Phenotypic heterogeneity in a large Thai slow-channel congenital myasthenic syndrome kinship.

Authors:  Rawiphan Witoonpanich; Teeratorn Pulkes; Charungthai Dejthevaporn; Praphan Yodnopklao; Pirada Witoonpanich; Suppachok Wetchaphanphesat; Joan M Brengman; Andrew G Engel
Journal:  Neuromuscul Disord       Date:  2011-03       Impact factor: 4.296

Review 4.  Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease.

Authors:  David N Cooper; Michael Krawczak; Constantin Polychronakos; Chris Tyler-Smith; Hildegard Kehrer-Sawatzki
Journal:  Hum Genet       Date:  2013-07-03       Impact factor: 4.132

Review 5.  RNAi: a potential new class of therapeutic for human genetic disease.

Authors:  Attila A Seyhan
Journal:  Hum Genet       Date:  2011-05-03       Impact factor: 4.132

Review 6.  The therapy of congenital myasthenic syndromes.

Authors:  Andrew G Engel
Journal:  Neurotherapeutics       Date:  2007-04       Impact factor: 7.620

Review 7.  Therapeutic strategies in congenital myasthenic syndromes.

Authors:  Ulrike Schara; Hanns Lochmüller
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

8.  Properties of the human muscle nicotinic receptor, and of the slow-channel myasthenic syndrome mutant epsilonL221F, inferred from maximum likelihood fits.

Authors:  C J Hatton; C Shelley; M Brydson; D Beeson; D Colquhoun
Journal:  J Physiol       Date:  2003-01-24       Impact factor: 5.182

9.  Selective cleavage of AChR cRNAs harbouring mutations underlying the slow channel myasthenic syndrome by hammerhead ribozymes.

Authors:  Amr Abdelgany; John Ealing; Matthew Wood; David Beeson
Journal:  J RNAi Gene Silencing       Date:  2005-07-28

10.  Selective DNAzyme-mediated cleavage of AChR mutant transcripts by targeting the mutation site or through mismatches in the binding arm.

Authors:  Amr Abdelgany; John Ealing; Matthew Wood; David Beeson
Journal:  J RNAi Gene Silencing       Date:  2005-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.